Rapport Therapeutics (RAPP) Interest & Investment Income (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Interest & Investment Income of $4.4 million for Q1 2026, up 43.12% year-over-year from $3.0 million in Q1 2025, and down 8.18% quarter-over-quarter from $4.7 million in Q4 2025.
Rapport Therapeutics (RAPP) Interest & Investment Income (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Interest & Investment Income for 4 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 43.12% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $14.9 million (up 11.68% YoY), while the FY2025 annual figure was $13.6 million, up 12.18% from the prior year.
- Interest & Investment Income retreated to $4.4 million in Q1 2026 per RAPP's latest filing, from $4.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.7 million in Q4 2025 and bottomed at $221000.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $2.7 million across 4 years, with a median of $2.9 million in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1112.22% — and 2025, when it declined 25.4%.
- Rapport Therapeutics' Interest & Investment Income stood at $1.4 million in 2023, then surged by 157.53% to $3.5 million in 2024, then surged by 34.03% to $4.7 million in 2025, then fell by 8.18% to $4.4 million in 2026.
- Business Quant data shows RAPP's Interest & Investment Income at $4.4 million in Q1 2026, $4.7 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 4.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.19 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.54 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 2.68 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 856,000.00 |
| Jun 30, 2023 | 221,000.00 |